Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The use of perhexiline maleate as an antianginal agent is occasionally associated with side effects, particularly neuropathy and liver damage. The reason why some individuals develop these toxic reactions is not clear, though some evidence suggests that they may result from impaired oxidative metabolism, due to genetic or hepatic factors, and consequential accumulation of the drug in toxic concentrations. Drug oxidation was measured with an oxidation phenotyping procedure in 34 patients treated with perhexiline, 20 of whom had developed neuropathy and 14 of whom had not. Most of the 20 patients with neuropathy, but not the unaffected patients, showed an impaired ability to effect metabolic drug oxidation. This impairment was independent of hepatic function, concurrent drug therapy, or tobacco or alcohol consumption. The fact that the ability to oxidise several drugs is genetically controlled points to a genetic susceptibility to developing neuropathy in response to perhexiline. Routine determination of the drug oxidation phenotype might lead to safer use of perhexiline by predicting patients who may be more at risk of developing a neuropathic reaction associated with its long-term use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
Self-citationEvans, D. A., Mahgoub, A., Sloan, T. P., Idle, J. R., & Smith, R. L. (1980) · Journal of Medical Genetics · doi:10.1136/jmg.17.2.102 · Cited by 536
Self-citationPerhexiline Maleate-Induced Cirrhosis
Pessayre, D., Bichara, M., Feldmann, G., Degott, C., Potet, F., & Benhamou, J.-P. (1979) · Gastroenterology · doi:10.1016/s0016-5085(79)80145-6 · Cited by 164
Polymorphism of carbon oxidation of drugs and clinical implications.
Sloan, T. P., Mahgoub, A., Lancaster, R., Idle, J. R., & Smith, R. L. (1978) · BMJ · doi:10.1136/bmj.2.6138.655 · Cited by 116
Self-citationProximal myopathy after perhexiline maleate treatment.
TOMLINSON, I. W., & Rosenthal, F. D. (1977) · BMJ · doi:10.1136/bmj.1.6072.1319 · Cited by 36
Toxicological Implications of Polymorphic Drug Metabolism
Ritchie, J., Sloan, T. P., Idle, J. R., & Smith, R. L. (1980) · Novartis Foundation symposium · doi:10.1002/9780470720592.ch12 · Cited by 32
Self-citation
Cited by
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Guengerich, F. P. (1995) · Cytochrome P450 · doi:10.1007/978-1-4757-2391-5_14 · Cited by 728
Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity
Fromenty, B., & Pessayre, D. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00012-6 · Cited by 665
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
Ingelman-Sundberg, M., Oscarson, M., & McLellan, R. A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01363-2 · Cited by 539
Metadata
- Authors
- Shah, R. R., Oates, N. S., Idle, J. R., Smith, R. L., & Lockhart, J. D.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1982-01-30
- Volume
- 284
- Issue
- 6312
- Pages
- 295-299
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2002945788
- Cited by
- 210
- References
- 6
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.